Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.2.2
Commitments and Contingencies (Details Narrative)
3 Months Ended 9 Months Ended
May 13, 2022
USD ($)
Feb. 08, 2022
USD ($)
Nov. 19, 2021
USD ($)
ft²
Mar. 26, 2021
USD ($)
Oct. 05, 2020
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Loss Contingencies [Line Items]                  
Monetary damages estimated amount $ 370,000                
Project fee               $ 2,100,000  
Project fee incurred               924,000  
Research and development expense           $ 2,743,000 $ 1,008,000 5,969,000 $ 3,287,000
Remaining commitments           601,000   601,000  
Other Commitments, Description         On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. The Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13 million, of which $10.5 million was incurred and recorded in prior years.        
Patent expense           90,000 67,000 313,000 339,000
Rent expense   $ 415 $ 9,450     29,000   87,000  
Scientific Research Agreement [Member]                  
Loss Contingencies [Line Items]                  
Research and development expense           192,000 541,000 575,000 541,000
Master Services Agreement [Member]                  
Loss Contingencies [Line Items]                  
Research and development arrangement               13,000,000  
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross               10,500,000  
Master Service Agreement [Member]                  
Loss Contingencies [Line Items]                  
Research and development expense           720,000 $ 528,000 1,900,000 $ 677,000
2016 Patent Exclusive License Agreement [Member]                  
Loss Contingencies [Line Items]                  
Proceeds from upfront amount           200,000   200,000  
Maintenance fee               100,000  
Performance milestone payments               3,100,000  
Sales milestone payments               1,000,000.0  
Gross sales               250,000,000  
Sales revenue               5,000,000.0  
Cumulative gross sales               $ 500,000,000  
2016 Patent Exclusive License Agreement [Member] | Minimum [Member]                  
Loss Contingencies [Line Items]                  
Royalty fee percentage               4.00%  
Annual royalty payments               $ 250,000  
2016 Patent Exclusive License Agreement [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Royalty fee percentage               6.00%  
Annual royalty payments               $ 5,000,000.0  
2021 Patent License Agreement [Member]                  
Loss Contingencies [Line Items]                  
Research and development expense           $ 0   $ 0  
Maintenance fee       $ 2,000,000.0          
Annual royalty payments       250,000          
Performance milestone payments       3,100,000          
Sales milestone payments       1,000,000.0          
Gross sales       250,000,000          
Sales revenue       5,000,000.0          
Cumulative gross sales       500,000,000          
Upfront license fee       20,000          
License maintenance fee, receivable       $ 5,000          
2021 Patent License Agreement [Member] | Minimum [Member]                  
Loss Contingencies [Line Items]                  
Net sales percentage       2.50%          
2021 Patent License Agreement [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Net sales percentage       5.00%          
Lease Agreements [Member]                  
Loss Contingencies [Line Items]                  
Area of land | ft²     4,500            
Commencement date     commencement date of January 1, 2022 and maturing on June 30, 2024